Patent ID: 8906606
Filing Date: 2014-12-09
Classification: A61P,C12N,C12Y

Abstract:
1. A method for evaluating breast cancer tissue derived from a patient, comprising the steps of: (a) obtaining a sample of breast cancer tissue from the patient, (b) evaluating the sample of breast cancer tissues to determine expression levels of plurality of genes selected from the group consisting of SPARC, IL13RA2, KLRC1 and KLRC2, MMP1, KYNU, EREG, TNC, ISG20, ALDH3A1, KRTHB1, PTGS2, LAPTM5, C10orf116, ROBO1, SPANXC, ANGPTL4, FSCN1, SOX4, SPANXB1 and SPANXC, COL6A1, CXCL1, MMP2, STOM, GPR153, MAN1A1, C14orf139, CASP1, IGSF4, LTBP1, NR2F1, EMP1, ID1, CNOT2, VCAM1, OLFML2A, NEDD9, CSF2RA, MOCOS, EPHX1, MBNL2, LOC388483, GSN, MYH10, ARNT2, RARRES3, EFEMP1, MATN2, LY6E, HLA-DPA1, ASMTL, ABCC3, KIAA1199, CXCR4, and PARD6B to obtain a sample signature for the cancer tissue sample, wherein the evaluation is performed by a method selected from the group consisting of binding of complementary oligonucleotide probes, RT-PCR, nucleic acid microarray analysis, binding of RNA specific antibodies, protein-ligand binding assays, protein immunoassays and protein microarray assays, and (c) comparing the sample signature to a reference signature, wherein the reference signature defines a standard expression level for each gene and a significant change direction for each gene, wherein the significant change direction is upregulation if the gene is SPARC, IL13RA2, KLRC1 and KLRC2, MMP1, KYNU, EREG, TNC, ISG20, ALDH3A1, KRTHB1, PTGS2, LAPTM5, C10orf116, ROBO1, SPANXC, ANGPTL4, FSCN1, SOX4, SPANXB1 and SPANXC, COL6A1, CXCL1, MMP2, STOM, GPR153, MAN1A1, C14orf139, CASP1, IGSF4, LTBP1, NR2F1, EMP1, ID1, CNOT2, or VCAM1 and downregulation if the gene is OLFML2A, NEDD9, CSF2RA, MOCOS, EPHX1, MBNL2, LOC388483, GSN, MYH10, ARNT2, RARRES3, EFEMP1, MATN2, LY6E, HLA-DPA1, ASMTL, ABCC3, KIAA1199, CXCR4, or PARD6B, and wherein a difference in the expression level in the sample signature that differs from the reference signature level for the gene in the significant change direction for the gene for at least a predetermined number of the genes tested is indicative that the patient has an increased risk of lung metastasis of the breast cancer.